ARWR ▼ -3.8% - Arrowhead Pharmaceuticals, Inc. $ARWR - Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia Arrowhead Pharmaceuticals shares fell 3.8% despite positive Phase 3 data showing that its experimental drug plozasiran reduced acute pancreatitis events in patients with severe hypertriglyceridemia. The decline suggests investors may have had higher expectations for the trial results, or there could be concerns about other aspects of the data not detailed in the headline, such as safety findings or the magnitude of the benefit compared to existing treatments. 30-AUG-2026 11:40 AM ET